GRID2 · rs17020773
Stands on its own. Nothing else here links to this position yet — but the page above is the point: what the research found, what each genotype means, and where it came from, in language you can read. Links to conditions, drugs and the senses appear automatically if we write them.
What the study found
Who was studied 4,900 European ancestry individuals.
The effect Each copy of the C allele carried 1.86 times the odds of Chemotherapy induced time to first peripheral neuropathy in cancer (95% confidence interval 1.5-2.31); p = 2 × 10−8.
How common The C allele had a frequency of about 3% in the people studied.
Where it sits Chromosome 4, band 4q22.2 — in an intron of GRID2.
rs17020773 is a single position in the genome, in or near the GRID2 gene. Published research associates it with chemotherapy induced time to first peripheral neuropathy in cancer. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
GWAS Catalog, Genome medicine 2023, PMID:37344884. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Chemotherapy induced time to first peripheral neuropathy in cancer (rs17020773). MyGeneLog™. https://www.mygenelog.com/variants/rs17020773